Cellular responses to EGFR inhibitors and their relevance to cancer therapy

被引:173
作者
Dutta, Pinaki R. [1 ]
Malty, Amit [1 ]
机构
[1] Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA
关键词
EGER inhibitor; epidermal growth factor receptor; radiosensitization; signaling; chemotherapy;
D O I
10.1016/j.canlet.2007.02.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
EGER is a trans-membrane receptor tyrosine kinase that belongs to the HER family of receptors. The EGER family plays an essential role in normal organ development by mediating morphogenesis and differentiation. Unlike normal cells that have tight regulatory mechanisms controlling EGER pathways, tumor cells often have dysregulated EGER signaling through receptor overexpression and/or mutation. This leads to proliferation under adverse conditions, invasion of surrounding tissues, and increased angiogenesis as well as resistance to radiation and chemotherapy. Therefore, EGER is a legitimate therapeutic target. Numerous EGFR inhibitors are under development, but to date only four of them are FDA-approved, including two that inhibit the receptor's intracellular tyrosine kinase activity (gefitinib and erlotinib) and two that block extracellular ligand binding (cetuximab, and most recently panitumumab). In this review, we focus on how these different inhibitors affect EGFR signaling and the mechanisms by which they potentiate the effects of chemotherapy and radiation therapy. Numerous clinical trials have been conducted with these agents either as monotherapy, in combination with chemotherapy, or concurrently with radiation. Unfortunately, many of the clinical trials reported so far have shown at best limited gains; therefore, understanding the actions of these agents is essential to improving their efficacy in the treatment of cancers. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:165 / 177
页数:13
相关论文
共 116 条
  • [111] The epidermal growth factor receptor and its inhibition in cancer therapy
    Woodburn, JR
    [J]. PHARMACOLOGY & THERAPEUTICS, 1999, 82 (2-3) : 241 - 250
  • [112] Wu XP, 1996, ONCOGENE, V12, P1397
  • [113] Characterization of sequence-dependent synergy between ZD1839 ('Iressa') and oxaliplatin
    Xu, JM
    Azzariti, A
    Severino, M
    Lu, B
    Colucci, G
    Paradiso, A
    [J]. BIOCHEMICAL PHARMACOLOGY, 2003, 66 (04) : 551 - 563
  • [114] Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
    Yang, XD
    Jia, XC
    Corvalan, JRF
    Wang, P
    Davis, CG
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 38 (01) : 17 - 23
  • [115] Yarden Y, 2001, EUR J CANCER, V37, pS3
  • [116] Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition
    Zips, D
    Eicheler, W
    Geyer, P
    Hessel, F
    Dörfler, A
    Thames, HD
    Haberey, M
    Baumann, M
    [J]. CANCER RESEARCH, 2005, 65 (12) : 5374 - 5379